13066-01-8

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-(2-Methoxyphenoxy)aniline is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its role in creating essential compounds with specific therapeutic or pesticidal properties.
Used in Dye and Pigment Manufacturing:
4-(2-Methoxyphenoxy)aniline is used as a key component in the production of dyes and pigments, leveraging its capacity to form stable and vibrant colors for a wide range of applications.
Used in Organic Compound Production:
As an important building block, 4-(2-Methoxyphenoxy)aniline is utilized in various industries for the production of a diverse array of organic compounds, contributing to the development of new materials and chemical products.

InChI:InChI=1/C13H13NO2/c1-15-12-4-2-3-5-13(12)16-11-8-6-10(14)7-9-11/h2-9H,14H2,1H3

Upstream product

• 32795-85-0 2-methoxyphenyl 4'-nitrophenyl ether 
• 7803-57-8 hydrazine hydrate 
• 90-05-1 2-methoxy-phenol 
• 100-00-5 4-chlorobenzonitrile 
• 5633-98-7 potassium guaiacolate 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 781653-01-8 2'-methoxy-4-bromodiphenyl ether 
• 860518-93-0 1-(4-iodo-phenoxy)-2-methoxy-benzene 
• 77725-94-1 [4-(2-Methoxy-phenoxy)-phenyl]-quinazolin-4-yl-amine 
• 304904-38-9 4-(4-(2-methoxyphenoxy)-anilino)-3-chloro-6,7-dimethoxyquinoline 
• 304904-39-0 4-(4-(2-methoxyphenoxy)-anilino)-3-bromo-6,7-dimethoxyquinoline 
• 78338-67-7 4-(2'-methoxyphenoxy)benzonitrile 
• 860577-87-3 acetic acid-[4-(2-methoxy-5-nitro-phenoxy)-2-nitro-anilide] 
• 860585-36-0 4-(2-methoxy-5-nitro-phenoxy)-2-nitro-aniline 
• 860577-97-5 acetic acid-[4-(2-methoxy-phenoxy)-2-nitro-anilide] 

Relevant academic research and scientific papers

Structural optimization and structure–activity relationship of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (hDHODH), one of the attractive targets for the development of immunosuppressive drugs, is also a potential target of anticancer drugs and anti-leukemic drugs. The development of promising hDHODH inhibitors is in high demand. Based on the unique binding mode of our previous reported 4-thiazolidinone derivatives, via molecular docking method, three new series 4-thiazolidinone derivatives were designed and synthesized as hDHODH inhibitors. The preliminary structure–activity relationship was investigated. Compound 9 of biphenyl series and compound 37 of amide series displayed IC50 values of 1.32 μM and 1.45 μM, respectively. This research will provide valuable reference for the research of new structures of hDHODH inhibitors.

AGRICULTURAL CHEMICALS

The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases ofplants.

Discovery of 1,2,4-triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex II and complex III

Respiratory chain succinate-ubiquinone oxidoreductase (SQR or complex II) and ubihydroquinone-cytochrome (cyt) c oxidoreductase (cyt bc1 or complex III) have been demonstrated as the promising targets of numerous antibiotics and fungicides. As a continuation of our research work on the development of new fungicides, a series of 1,2,4-triazole-1,3-disulfonamide derivatives with dual functions targeting both SQR and cyt bc1 were designed and synthesized by coupling diverse diphenyl ether moieties with triazolesulfonamide units. These newly synthesized compounds were characterized by elemental analyses, 1H NMR and ESI-MS spectrometry. The in vitro assay indicated that most of the synthesized compounds displayed good inhibition against porcine succinate-cytochrome reductase (SCR) with IC50 values ranging from 3.2 to 81.8 μM, revealing much higher activity than that of the commercial control amisulbrom whose IC50 value is 93.0 μM. Further evaluation against the respective SQR and cyt bc1 indicated that most compounds exhibited SQR-inhibiting activity as well as cyt bc1-inhibiting activity, but the inhibition potency against SQR is much higher than that against cyt bc1, showing that the SCR inhibition might be contributed greatly by the SQR inhibition. The further antibacterial evaluation against Xanthomonas oryzae pv. oryzae revealed that four compounds showed excellent potency at the concentration of 20 μg mL-1. In particular, compounds 6h and 6j exhibited much better antibacterial activity than the commercial control bismerthiazol in terms of their EC50. Impressively, 6j has an EC90 of 33.62 μg mL-1, more than 10-fold higher than that of bismerthiazol.

Derivatives of quinoline as inhibitors for MEK

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof. wherein: n is 0-1; X and Y are independently selected from -NH-, -O-, -S-, or -NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0,or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.

4-Substituted anilides as selective melatonin MT2 receptor agonists

A series of 4-substituted anilides with human melatonergic affinity is reported. Butyramides 26, 39, 42, 52, 57, and 58 all demonstrated subnanomolar MT2 binding affinity and MT2 selectivity of at least 70-fold over the MT1 receptor. Compound 26 demonstrated full agonism at the MT2 receptor.

Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.